ADIPOQ and metabolic syndrome: Research demonstrated PPARγ agonists would increase the circulating adiponectin in a metabolic syndrome rat model [55], and an epidemiological study proved that PPARγ gene polymorphism would affect the serum adiponectin levels [56].